Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

Also called NCT05957887

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Mohamed Nabil Elkholy (from the registry)
Registry
  • NCT NCT05957887
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05957887. Randomized; no masking; primary purpose treatment. Start 2022-04-15 (actual); primary completion 2025-03-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients
Condition
STEMI
Intervention (Drug)
Dapagliflozin
Lead sponsor
Mohamed Nabil Elkholy (class: other)

Record details

Record id
cardio:ct-nct05957887
Content hash
c8563c58c07d51bdfae882b6fbdf4caeeee247ef9c823f3b1895b10e1b2be4a7